Retatrutide is a GIP, GLP-1, and glucagon triple hormone receptor agonist, under clinical development for type 2 diabetes, obesity, and related complications. We aimed to assess the efficacy and safety of retatrutide as a monotherapy in people with type 2 diabetes that is inadequately controlled by diet and exercise alone. In this 40-week, phase 3, randomised, double-blind, placebo-controlled trial at 48 sites in the USA, Mexico, and India, we recruited adults (aged ≥18 years) with type 2 diabetes that is inadequately controlled by diet and exercise alone, glycated haemoglobin (HbA 1c ) between 7·0% and 9·5% (53-80 mmol/mol), and BMI of at least 23 kg/m 2 .
What the study reported
How to read it carefully
Confirm the complete study design, intervention identity, population or model, outcomes, statistical context, and limitations in the linked source before approval.